Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: Gutterball who wrote (2727)	11/24/1998 10:15:00 AM
From: shero	Respond to of 3702

It seems all the science discussion has moved to Yahoo!! and to Terrys. A nice change for yahoo. InvestorCG--someone on Yahoo stated that the stock was under accumulation--I think is is, too. Then someone asked how one can tell if a stock is under accumulation and someone answered back that you can tell that because the stock will go up. That is not necessarily true. A savvy investor could accumulate a huge position in this company just by having a market maker stay on the bid and take what comes in. And obviously someone is doing just that cause the stock doesn't seem to be going down. I don't think Swartz is playing games w/this stock. He arranged the $8MM financing before the disasterous Cappello deal. That deal was done at about $3 and promptly ran up to about $8. I remember that clearly because that was the one time in my life I was smart enough to sell at the top. But not smart enough to sell it all and I bought it back between $2 and$3, so I'm not really very smart at all. But to the point Swartz has always, at least in the past, been a long term player. I'm starting to hear rumblings--positive--about an oncoming PR extravaganda. I'm hoping Rubenstein will trot out a couple of the TNT patients. Some were treated over 4 or 5 months ago, and since we aren't in a Phase 3 for TNT there is no penalty for talking about results. As far as the LYM trials, I believe that Dr. Oliver made it pretty clear that the company will not release any interim results because the FDA will "ding" them points. So barring any news on a licensing deal we just will have to wait for the end of the trial to hear anything on LYM. But you can bet your bottom dollar that the results are good if someone steps up and licenses the drug. And of course Thorpe presents in London in the first week of Dec. I hope no one takes this as a tout but I don't think there will be many more opportunities to buy this stock at $1. Certainly not after January.